Jay R. Luly

2022

In 2022, Jay R. Luly earned a total compensation of $7.3M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 37% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$483,032
Option Awards$3,739,269
Salary$725,050
Stock Awards$2,305,881
Other$19,424
Total$7,272,656

Luly received $3.7M in option awards, accounting for 51% of the total pay in 2022.

Luly also received $483K in non-equity incentive plan, $725.1K in salary, $2.3M in stock awards and $19.4K in other compensation.

Rankings

In 2022, Jay R. Luly's compensation ranked 394th out of 5,760 executives tracked by ExecPay. In other words, Luly earned more than 93.2% of executives.

ClassificationRankingPercentile
All
394
out of 5,760
93rd
Division
Manufacturing
161
out of 3,136
95th
Major group
Chemicals And Allied Products
41
out of 1,422
97th
Industry group
Drugs
30
out of 1,323
98th
Industry
Pharmaceutical Preparations
22
out of 969
98th

Pay ratio

Jay R. Luly's Pay$7,272,656
Median Employee's Pay$249,345
Pay Ratio

29

to 1

In 2022, the annual total compensation of Jay R. Luly was $7,272,656.

The annual total compensation of the median employee at Enanta Pharmaceuticals was $249,345.

The ratio of Jay R. Luly's pay to the pay of median employee was therefore 29 to one.

Source: SEC filing on January 20, 2023.

Luly's colleagues

We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2022.

2022

Scott Rottinghaus

Enanta Pharmaceuticals

Chief Medical Officer

2022

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

2022

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

2022

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like